Clinical trials: Depression - Major Depressive Disorder
Major Depressive Disorder
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in…
- Trial name
- NCT03357796
- Testing
- LY03005, Pristiq
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Recurrent Major Depressive Disorder With Atypical Features
Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features
The purpose of this study is to determine a dose of the investigational drug betahistine dihydrochloride that is both well tolerated and potentially effective in treating the symptoms of atypical depression.
- Trial name
- NCT00585585
- Testing
- betahistine dihydrochloride
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Cincinnati
Depression
Major Depressive Disorder (MDD)
The purpose of this study is to assess the effectiveness of systematic screening for depression in high-risk patient participants in everyday clinical practice.
- Trial name
- NCT01662817
- Testing
- Intervention, Control
- Where
- Spain
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depression - Major Depressive Disorder, Depression Disorders
Meditative Neurofeedback for Depression
The goal of this study is to test a meditative neurofeedback intervention for depressed mood.
- Trial name
- MediNF (NCT06675240)
- Testing
- MediNF
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, San Diego
Depressive Disorder, Major
Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)
The purpose of this study is to assess the efficacy, safety and tolerability of GW679769 patients with Major depressive Disorder (MDD).
- Trial name
- NCT00413023
- Testing
- GW679769
- Where
- 39 sites in Argentina, Belgium and 9 more
- Volunteers
- 348 people
- Sponsor
- GlaxoSmithKline
Depression
BEAT-IT: Behavioural Activation and Severe Learning Disabilities
Depression is common, but no psychological interventions have been tested to see if they work for adults with severe intellectual disabilities.
- Trial name
- NCT04744259
- Testing
- Behavioural Activation
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- NHS Greater Glasgow and Clyde
Major Depressive Disorder, Depression
Effect of the Menstrual Cycle on the Symptoms of Depression and Treatment Response
Objectives: This prospective investigation will compare premenopausal, perimenopausal and postmenopausal women's response to antidepressant medication.
- Trial name
- NCT00188396
- Testing
- Citalopram
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- University Health Network, Toronto
Depression - Major Depressive Disorder, Psychological Well Being
Peer-Supported E-Health Intervention for College Student Weight Management and Mental Health
This study will test whether adding peer support and online education can help college students manage their weight and improve their mood: we plan to enroll 300 full-time university students and randomly assign them to one of…
- Conditions
- Depression - Major Depressive Disorder, Psychological Well Being, Obesity Prevention
- Trial name
- NCT06966661
- Testing
- Peer Support Intervention, Peer Support and eHealth Intervention
- Where
- China
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Jinan University Guangzhou
Mood Disorders, Bipolar Disorder
Mood Patient Powered Research Network (MoodNetwork)
The MoodNetwork, a patient-powered research network (PPRN), is one of 18 PPRNs participating in Patient-Centered Outcomes Research Institute's (PCORI) PCORnet network.
- Conditions
- Mood Disorders, Bipolar Disorder, Major Depressive Disorder, Depression
- Trial name
- NCT02453438
- Testing
- Patient Reported Outcomes
- Where
- United States
- Volunteers
- 5,716 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder
This primary purpose of this study is to assess the efficacy and safety of Effexor XR in preventing recurrence in Chinese patients with recurrent major depressive disorder (MDD) following a 1-year maintenance treatment after an…
- Trial name
- NCT00878748
- Testing
- Effexor XR, Effexor XR discontinue
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder
To evaluate the efficacy of quetiapine fumarate sustained release (Seroquel SR™) in combination with an antidepressant versus an antidepressant alone in patients with Major Depressive Disorder.
- Trial name
- ONYX (NCT00351910)
- Testing
- Quetiapine, Amitriptyline, Bupropion
- Where
- 72 sites in Australia, Belgium and 10 more
- Volunteers
- 494 people
- Sponsor
- AstraZeneca
Depressive Disorder, Major
Probing Prefrontal Cortex Hemodynamic Alterations for Major Depression Disorder
Major depression disorder (MDD) has high estimated lifetime prevalence rates of 16.6%. Currently, the diagnosis for the MDD mainly depends on patients' reports of symptoms, observed behaviors and disease course.
- Trial name
- MDD (NCT03595020)
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital
Depression - Major Depressive Disorder, Depression Anxiety Disorder
Evaluating the Effectiveness and Acceptability of a GPT-4o and RAG-Based Voice Chatbot for Depression Screening Using PHQ-9
This study aims to assess the feasibility and acceptability of a voice-based chatbot, powered by GPT-4o and Retrieval-Augmented Generation (RAG), for conducting depression screening using the Patient Health Questionnaire-9…
- Trial name
- GPT4-RAG-PHQ (NCT06801925)
- Testing
- GPT-4o and RAG Voice Chatbot for PHQ-9 Screening
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University College, London
Depression, Major Depressive Disorder
Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine
The purposes of this project are to examine the feasibility, safety, tolerability and clinical effect of low-dose buprenorphine as a novel treatment for late-life treatment-resistant depression and to develop preliminary data…
- Trial name
- IRLGREY-B (NCT02176291)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Jordan F. Karp
Depression, Bipolar Disorder
Insulin Resistance in Patients With Major Depression
The purpose of this study is to study the relationship between insulin and glucose action and neuropsychological functioning (memory, attention, general thinking abilities) in persons with depression.
- Conditions
- Depression, Bipolar Disorder, Mood Disorders, Insulin Resistance
- Trial name
- NCT01106313
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Stanford University
Depressive Disorder
A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)
The purpose of the study is to evaluate the long-term efficacy and safety of Saredutant in patients with depression. The primary objective is to evaluate the efficacy and safety of Saredutant 100 mg once daily compared to placebo…
- Trial name
- NCT00336713
- Testing
- Saredutant (SR48968C)
- Where
- United States
- Volunteers
- 430 people
- Sponsor
- Sanofi
Major Depressive Disorder
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder…
- Trial name
- NCT06223880
- Testing
- AXS-05, Bupropion
- Where
- 40 sites in United States
- Volunteers
- 350 people
- Sponsor
- Axsome Therapeutics, Inc.
Major Depression
Pharmacotherapy in Depression With Panic Spectrum
This research study is being conducted to find out if certain individuals benefit from taking medication for their depression with a low dose of the antidepressant medication Zoloft.
- Trial name
- NCT00177996
- Testing
- sertraline hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder
Accelerated rTMS for Treatment-Resistant Major Depression
High frequency repetitive transcranial magnetic stimulation (HF-rTMS) has shown safety and efficacy for treatment-resistant depression, but requires daily treatment for 4-6 weeks.
- Trial name
- NCT02125799
- Testing
- Accelerated HF-rTMS (Magstim Rapid 2 stimulator)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Douglas Mental Health University Institute
Major Depression, Temporal Lobe Epilepsy
Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy
This is a research study evaluating the use of escitalopram (Lexapro®) for the treatment of major depression in subjects with temporal lobe epilepsy.
- Trial name
- NCT00595699
- Testing
- escitalopram
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Conrad, Erich J., M.D.